


DISCOVER A SOURCE OF EOSINOPHILIC ESOPHAGITIS (EoE)

LOOK BEYOND EOSINOPHILS TO TYPE 2 INFLAMMATION




DISCOVER > RECOGNIZE > RETHINK EoE AND THE ROLE OF TYPE 2 INFLAMMATION IN ITS PATHOGENESIS

Consider the overall disease burden when evaluating EoE

Eosinophilic esophagitis is driven primarily by IL-4, IL-13, and IL-5, which are key cytokines of Type 2 inflammation^{1,2}

IL-4 and IL-13 have a central impact on the complex pathophysiology of Type 2 inflammation in eosinophilic esophagitis

Understand the impact of Type 2 inflammation on symptoms of EoE²⁻⁴



Eosinophil trafficking

Epithelial barrier dysfunction

Remodeling and fibrosis, leading to strictures, rings, furrows, edema, exudates, and smooth muscle contraction



Symptoms

Treatment goals in eosinophilic esophagitis include^{5,6}:



Clinical remission

Lack or reduction of EoE-attributed symptoms



Endoscopic remission

Absence of inflammatory signs (eg, white exudates, furrows, edema), EREFS score ≤ 2



Histological inflammatory remission

Peak eosinophil count ≤ 6 EOS/HPF histology/ HE stain

When evaluating patients with eosinophilic esophagitis, consider the impact of Type 2 inflammation

EOS, eosinophil; EREFS, endoscopic reference score; HE, hematoxylin and eosin; HPF, high-power field; ILC2, type 2 innate lymphoid cells.

References: 1. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov.* 2016;15(1):35-50. 2. Hill DA, Spergel JM. The immunologic mechanisms of eosinophilic esophagitis. *Curr Allergy Asthma Rep.* 2016;16(2):9. 3. Gomez Torrijos E, Gonzalez-Mendiola R, Alvarado M, et al. Eosinophilic esophagitis: review and update. *Front Med (Lausanne).* 2018;5:247. 4. Furuta GT, Katzka DA. Eosinophilic esophagitis. *N Engl J Med.* 2015;373(17):1640-1648. 5. Safroneeva E, Straumann A, Coslovsky M, et al; International Eosinophilic Esophagitis Activity Index Study Group. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. *Gastroenterology.* 2016;150(3):581-590.e4. 6. Ma C, Schoepfer AM, Dellon ES, et al; The COREOS Collaborators. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). *J Allergy Clin Immunol.* Accepted manuscript. 2021. doi.org/10.1016/j.jaci.2021.07.001